Sign in
Not yet recruitingPhase 2

Psilocybin-assisted Therapy for Post-Traumatic Stress Disorder in Survivors of Intimate Partner Violence

Key facts

Who runs it
University of Calgary
Where
Canada2 sites in 1 countryChoose a country to see its sites
Trial code
Status
Not yet recruiting
Phase
Phase 2
People taking part
76 people, planned
Started
1 Oct 2026
Expected to end
1 Aug 2029
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Psilocybin
Record updated
8 September 2026

Who can take part

Age
18 years to 65 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Individuals of all sexes, gender identities, and ethnicities
  • Ages 19 to 65 years at the time of screening
  • At least 6 months since last IPV incident
  • A score of 1 on the Composite Abuse Scale with repetition of abusive events
  • Minimum PCL-5 score of ≥ 33
  • Limited lifetime use of serotonergic hallucinogens
  • Ability to read/write English

Who cannot take part

  • Severe or moderate substance use disorder other than nicotine in past 6 months
  • Lifetime diagnosis of schizophrenia or bipolar disorders (or first or second-degree relative)
  • Insulin-dependent diabetes; if taking oral hypoglycemic agent, then no history of hypoglycemia
  • Epilepsy with a history of seizures
  • Cognitive impairment (SLUMS score <20)
  • Any notable abnormality on ECG or routine medical blood laboratory test
  • Active suicidal ideation or serious attempt within the past 1 year
  • Current pregnancy or nursing, trying to become pregnant
  • Current or recent (within 12 weeks) participation in a clinical trial
  • Suffered a moderate/severe TBI at least once in lifetime
  • Suffered a mild TBI within the last 6 months
  • Any other circumstances that, in the opinion of the investigators, compromises participant safety
  • Not compelled to enter treatment to avoid legal consequences

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 65 years old?

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The goal of this randomized controlled trial is to evaluate the efficacy of psilocybin administered with Acceptance and Commitment Therapy (ACT) as an intervention to reduce post-traumatic stress disorder (PTSD) symptom burden in adult (aged 18-65) survivors of intimate partner violence (IPV).

Read full original descriptionShow less

This trail will test the following 2 aims:

AIM 1 : To compare the efficacy of a therapeutic psilocybin dose at improving outcomes on the PCL-5 and CAPS-5 as compared to an active control psilocybin dose in IPV survivors with chronic PTSD.

AIM 2: To evaluate the efficacy of psilocybin on quality of life, cognitive function, motor ability, depression, anxiety, and cognitive flexibility.

Participants will be asked to:

* Complete a 2 part screening process * Attend a baseline assessment * Complete a psychoeducation preparation session(s) * Attend psilocybin administration session (receive high dose [25mg] or low dose psilocybin [1mg]) * Complete 5-6 weekly sessions of ACT * Repeat outcome measures at 1-week, 4 weeks, 3 months (online questionnaires only), and 6 months post-psilocybin administration.

The 2 groups in the trial

  • High DoseTreatment being tested

    High Dose (25mg) PEX010 (Oral Psilocybin), 25mg; single dose (38 participants) administered 24hrs prior to first ACT session

  • Low DoseExisting treatment, for comparison

    Low Dose (5mg) PEX010 (Oral Psilocybin), 5mg; single dose (20 participants) administered 24hrs prior to first ACT session

    Treatment: Psilocybin

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Fit questions
Built from NCT06885996, who can take part
Record updated
8 September 2026